Karina Dalsgaard Sørensen
MOMA, Department of Molecular Medicine, University of Aarhus |
Prostate cancer (PC) is the most commonly diagnosed malignancy and the third leading cause of cancer-related death in males in Western countries, including Denmark. The widespread use of PSA testing to detect PC has led to an increased incidence of PC diagnosis, but also to significant over-diagnosis and over-treatment of clinically insignificant PC. Thus, a major challenge in PC management is to distinguish between cancers that will progress rapidly and become life-threatening, and cancers that will remain latent and not significantly affect the health of the patient.